Francis Crick Institute, London, UK.
Department of Medicine, Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York, NY, USA.
Lancet Microbe. 2024 Feb;5(2):e164-e172. doi: 10.1016/S2666-5247(23)00317-8. Epub 2024 Jan 9.
Clinical bedaquiline resistance predominantly involves mutations in mmpR5 (Rv0678). However, mmpR5 resistance-associated variants (RAVs) have a variable relationship with phenotypic Mycobacterium tuberculosis resistance. We did a systematic review to assess the maximal sensitivity of sequencing bedaquiline resistance-associated genes and evaluate the association between RAVs and phenotypic resistance, using traditional and machine-based learning techniques.
We screened public databases for articles published from database inception until Oct 31, 2022. Eligible studies performed sequencing of at least mmpR5 and atpE on clinically sourced M tuberculosis isolates and measured bedaquiline minimum inhibitory concentrations (MICs). A bias risk scoring tool was used to identify bias. Individual genetic mutations and corresponding MICs were aggregated, and odds ratios calculated to determine association of mutations with resistance. Machine-based learning methods were used to define test characteristics of parsimonious sets of diagnostic RAVs, and mmpR5 mutations were mapped to the protein structure to highlight mechanisms of resistance. This study was registered in the PROSPERO database (CRD42022346547).
18 eligible studies were identified, comprising 975 M tuberculosis isolates containing at least one potential RAV (mutation in mmpR5, atpE, atpB, or pepQ), with 201 (20·6%) showing phenotypic bedaquiline resistance. 84 (29·5%) of 285 resistant isolates had no candidate gene mutation. Sensitivity and positive predictive value of taking an any mutation approach was 69% and 14%, respectively. 13 mutations, all in mmpR5, had a significant association with a resistant MIC (adjusted p<0·05). Gradient-boosted machine classifier models for predicting intermediate or resistant and resistant phenotypes both had receiver operator characteristic c statistic of 0·73 (95% CI 0·70-0·76). Frameshift mutations clustered in the α1 helix DNA-binding domain, and substitutions in the α2 and α3 helix hinge region and in the α4 helix-binding domain.
Sequencing candidate genes is insufficiently sensitive to diagnose clinical bedaquiline resistance, but where identified, some mutations should be assumed to be associated with resistance. Genomic tools are most likely to be effective in combination with rapid phenotypic diagnostics. This study was limited by selective sampling in contributing studies and only considering single genetic loci as causative of resistance.
Francis Crick Institute and National Institute of Allergy and Infectious Diseases at the National Institutes of Health.
临床中主要涉及到突变 mmpR5(Rv0678)导致的贝达喹啉耐药。然而,mmpR5 耐药相关变异(RAV)与结核分枝杆菌表型耐药的关系存在差异。我们进行了一项系统评价,旨在评估测序贝达喹啉耐药相关基因的最大敏感性,并使用传统和基于机器的学习技术评估 RAV 与表型耐药之间的关联。
我们从数据库建立之初到 2022 年 10 月 31 日筛选了公共数据库中的文章。合格的研究对来自临床来源的 M 结核分枝杆菌分离株进行了至少 mmpR5 和 atpE 的测序,并测量了贝达喹啉最小抑菌浓度(MIC)。使用偏倚风险评分工具来识别偏倚。聚合单个基因突变和相应的 MIC 值,并计算比值比以确定突变与耐药性的相关性。使用基于机器的学习方法来定义简单的诊断 RAV 集的测试特征,并将 mmpR5 突变映射到蛋白质结构上以突出耐药机制。本研究已在 PROSPERO 数据库(CRD42022346547)中注册。
确定了 18 项合格的研究,包括含有至少一个潜在 RAV(mmpR5、atpE、atpB 或 pepQ 中的突变)的 975 株结核分枝杆菌分离株,其中 201 株(20.6%)表现出表型贝达喹啉耐药。285 株耐药分离株中有 84 株(29.5%)没有候选基因突变。采用任何突变方法的敏感性和阳性预测值分别为 69%和 14%。13 个突变,均位于 mmpR5 中,与耐药 MIC 有显著相关性(调整后 p<0.05)。预测中间或耐药表型和耐药表型的梯度提升机分类器模型的受试者工作特征曲线下面积均为 0.73(95%CI 0.70-0.76)。移码突变聚集在α1 螺旋 DNA 结合域,取代位于α2 和α3 螺旋铰链区以及α4 螺旋结合域。
测序候选基因不足以敏感地诊断临床贝达喹啉耐药,但在鉴定出这些基因时,应假定某些突变与耐药有关。基因组工具最有可能与快速表型诊断相结合发挥作用。本研究受到纳入研究中选择性采样的限制,并且仅考虑单一遗传位点是耐药的原因。
弗朗西斯·克里克研究所和美国国立卫生研究院过敏和传染病研究所国家过敏和传染病研究所。